Contribution from pathologist to the MDT meeting does not only include decision on malignancy, staging of tumor, and risk assessment based upon histological features. Also evaluation of tumor response to neoadjuvant or adjuvant treatment is important. Criteria for complete resection of cancers are also becoming more complex. The pathologist should deliver data for the prediction of clinical outcome. In screening programs, the key challenges are evaluation of risk factors in polyps and early cancers and identification of indicators of hereditary syndromes.